NASDAQ:ZGNX

Zogenix Stock Forecast, Price & News

$17.99
+0.20 (+1.12 %)
(As of 06/18/2021 12:00 AM ET)
Add
Compare
Today's Range
$17.43
$18.14
50-Day Range
$16.98
$19.66
52-Week Range
$16.73
$32.42
Volume1.63 million shs
Average Volume791,030 shs
Market Capitalization$1.00 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.43
30 days | 90 days | 365 days | Advanced Chart
Receive ZGNX News and Ratings via Email

Sign-up to receive the latest news and ratings for Zogenix and its competitors with MarketBeat's FREE daily newsletter.


Zogenix logo

About Zogenix

Zogenix, Inc., a biopharmaceutical company, develops and commercializes therapies to transform the lives of patients and their families living with rare diseases in the United States. The company's lead product candidate is the Fintepla, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome, as well as to treat seizures associated with Lennox-Gastaut syndrome; and that is in Phase II clinical trials for the treatment of other rare epileptic syndromes and diseases. It is also developing MT1621, an investigational therapy for the treatment of a rare genetic disorder called thymidine kinase 2 deficiency. Zogenix, Inc. has a collaboration with Tevard Biosciences for the research, development and commercialization of novel gene therapies for Dravet Syndrome and other genetic epilepsies. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was incorporated in 2006 and is headquartered in Emeryville, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.70 out of 5 stars

Medical Sector

333rd out of 2,097 stocks

Pharmaceutical Preparations Industry

156th out of 831 stocks

Analyst Opinion: 3.4Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Zogenix (NASDAQ:ZGNX) Frequently Asked Questions

Is Zogenix a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Zogenix in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Zogenix stock.
View analyst ratings for Zogenix
or view top-rated stocks.

What stocks does MarketBeat like better than Zogenix?

Wall Street analysts have given Zogenix a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Zogenix wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Zogenix's next earnings date?

Zogenix is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Zogenix
.

How were Zogenix's earnings last quarter?

Zogenix, Inc. (NASDAQ:ZGNX) posted its quarterly earnings results on Thursday, May, 6th. The company reported ($1.00) EPS for the quarter, missing the Zacks' consensus estimate of ($0.98) by $0.02. The company had revenue of $13.68 million for the quarter, compared to analysts' expectations of $12.34 million. Zogenix had a negative net margin of 917.30% and a negative trailing twelve-month return on equity of 60.93%. The firm's quarterly revenue was up 995.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.54) EPS.
View Zogenix's earnings history
.

How has Zogenix's stock been impacted by Coronavirus (COVID-19)?

Zogenix's stock was trading at $22.69 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ZGNX shares have decreased by 20.7% and is now trading at $17.99.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for ZGNX?

5 brokerages have issued 1 year price targets for Zogenix's stock. Their forecasts range from $48.00 to $65.00. On average, they expect Zogenix's share price to reach $59.00 in the next year. This suggests a possible upside of 228.0% from the stock's current price.
View analysts' price targets for Zogenix
or view top-rated stocks among Wall Street analysts.

Who are Zogenix's key executives?

Zogenix's management team includes the following people:
  • Dr. Stephen J. Farr, Co-Founder, CEO, Pres & Director (Age 62, Pay $1.02M)
  • Mr. Michael P. Smith, Exec. VP, CFO & Treasurer (Age 53, Pay $633.59k)
  • Ms. Shawnte M. Mitchell, Exec. VP, Gen. Counsel & Sec. (Age 43, Pay $715.4k)
  • Dr. Bradley S. Galer, Exec. VP & Chief Medical Officer (Age 59, Pay $641.62k)
  • Dr. Gail M. Farfel, Exec. VP & Chief Devel. Officer (Age 57, Pay $638.12k)
  • Mr. Ashish M. Sagrolikar, Exec. VP & Chief Commercial Officer (Age 54, Pay $616.98k)
  • Mr. Jeff D. Durflinger, VP of Technical Operations & Product Supply (Age 60)
  • Melinda Baker, Sr. Director of Corp. Communications
  • Mr. Bret E. Megargel, VP of Corp. Devel. (Age 52)
  • Mr. Stephen H. Jenner, VP of Marketing (Age 53)

What is Stephen Farr, Ph.D.'s approval rating as Zogenix's CEO?

7 employees have rated Zogenix CEO Stephen Farr, Ph.D. on Glassdoor.com. Stephen Farr, Ph.D. has an approval rating of 85% among Zogenix's employees.

Who are some of Zogenix's key competitors?

What other stocks do shareholders of Zogenix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zogenix investors own include GW Pharmaceuticals (GWPH), Gilead Sciences (GILD), Vanda Pharmaceuticals (VNDA), AbbVie (ABBV), QUALCOMM (QCOM), Advanced Micro Devices (AMD), (CGC), Sorrento Therapeutics (SRNE), Southwest Airlines (LUV) and Micron Technology (MU).

What is Zogenix's stock symbol?

Zogenix trades on the NASDAQ under the ticker symbol "ZGNX."

Who are Zogenix's major shareholders?

Zogenix's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include RA Capital Management L.P. (9.47%), BlackRock Inc. (8.82%), Morgan Stanley (6.71%), Franklin Resources Inc. (4.86%), Bank of New York Mellon Corp (4.31%) and Janus Henderson Group PLC (3.19%). Company insiders that own Zogenix stock include Ashish M Sagrolikar, Cam L Garner, Gail M Farfel, James B Breitmeyer, Mark C Wiggins, Michael P Smith, Renee P Tannenbaum and Stephen J Farr.
View institutional ownership trends for Zogenix
.

Which institutional investors are selling Zogenix stock?

ZGNX stock was sold by a variety of institutional investors in the last quarter, including Vivo Capital LLC, D. E. Shaw & Co. Inc., Millennium Management LLC, Woodline Partners LP, SG Americas Securities LLC, Voloridge Investment Management LLC, 683 Capital Management LLC, and Eversept Partners LP.
View insider buying and selling activity for Zogenix
or view top insider-selling stocks.

Which institutional investors are buying Zogenix stock?

ZGNX stock was acquired by a variety of institutional investors in the last quarter, including Artisan Partners Limited Partnership, Bridger Management LLC, Franklin Resources Inc., Assenagon Asset Management S.A., Morgan Stanley, Bank of New York Mellon Corp, BlackRock Inc., and Healthcare of Ontario Pension Plan Trust Fund. Company insiders that have bought Zogenix stock in the last two years include Ashish M Sagrolikar, Cam L Garner, Mark C Wiggins, and Renee P Tannenbaum.
View insider buying and selling activity for Zogenix
or or view top insider-buying stocks.

How do I buy shares of Zogenix?

Shares of ZGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Zogenix's stock price today?

One share of ZGNX stock can currently be purchased for approximately $17.99.

How much money does Zogenix make?

Zogenix has a market capitalization of $1.00 billion and generates $13.64 million in revenue each year. The company earns $-209,380,000.00 in net income (profit) each year or ($3.88) on an earnings per share basis.

How many employees does Zogenix have?

Zogenix employs 218 workers across the globe.

What is Zogenix's official website?

The official website for Zogenix is www.zogenix.com.

Where are Zogenix's headquarters?

Zogenix is headquartered at 5959 Horton Street Suite 500, EMERYVILLE CA, 94608.

How can I contact Zogenix?

Zogenix's mailing address is 5959 Horton Street Suite 500, EMERYVILLE CA, 94608. The company can be reached via phone at 510-550-8300 or via email at [email protected]


This page was last updated on 6/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.